CRISPR-Phage: Reprogramming the Microbe War

The microbial world, often unseen, dictates far more of our fate than we care to admit. For decades, humanity waged a chemical war against bacterial infections, a conflict once thought won decisively. Yet, the enemy adapted, evolving into formidable superbugs that laugh in the face of our most potent antibiotics. This isn't just a medical crisis; it's an existential threat to modern medicine, threatening to return us to a pre-antibiotic era where a simple cut could be a death sentence.

But what if the solution wasn't more chemical brute force, but surgical precision? What if we could reprogram the very viruses that naturally prey on bacteria, turning them into bespoke assassins capable of not just killing, but editing the resistance out of our microscopic adversaries? This isn't science fiction; it's the audacious promise of CRISPR-enhanced phage therapy, a convergence of two biotechnological titans poised to redefine infectious disease treatment.

This isn't merely an incremental improvement; it's a fundamental shift in strategy, moving from broad-spectrum carpet bombing to precision-guided munitions. The market, however, largely understates the scale of this disruption, still fixated on the slow, expensive grind of traditional drug discovery. For savvy investors, this disconnect presents a rare opportunity to get ahead of the curve, before the broader market recognizes the true potential of these microscopic genetic engineers.

The Battlefield: Where Superbugs Meet Surgical Precision

The global healthcare system stares down a barrel loaded with antibiotic resistance. The World Health Organization (WHO) declared antimicrobial resistance (AMR) one of the top 10 global public health threats facing humanity. Projections indicate that by 2050, AMR could cause 10 million deaths annually, surpassing cancer [1]. This isn't a distant problem; it's a present danger, eroding the efficacy of treatments for everything from pneumonia to routine surgeries.

Traditional antibiotic development, once a pharmaceutical gold rush, slowed to a trickle. The economic incentives are misaligned: new antibiotics are expensive to develop, used sparingly to prevent resistance, and often face rapid obsolescence as bacteria adapt. This creates a market failure, leaving a gaping void in our therapeutic arsenal against increasingly cunning pathogens.

This is where the counter-narrative begins. While the market frets over the dwindling pipeline of conventional drugs, a quiet revolution brews in bacteriophages—viruses that specifically infect and kill bacteria. Phage therapy itself isn't new, with roots tracing back over a century, particularly in Eastern Europe. Yet, its broader adoption has been hampered by issues of specificity, immunogenicity, and the sheer complexity of matching the right phage to the right bacterial strain.

The advent of CRISPR-Cas gene editing technology fundamentally changed the game. It provides the molecular scalpel needed to overcome these historical limitations, transforming phages from blunt instruments into highly programmable, precision-guided biological weapons. We are moving beyond simply using phages to engineering them, opening up a therapeutic frontier once unimaginable.

Key Takeaway: The looming superbug crisis, coupled with the systemic failure of traditional antibiotic development, creates an urgent demand for novel solutions. CRISPR-enhanced phage therapy is uniquely positioned to fulfill this, despite market underappreciation.

---

The Technology: Reprogramming Nature's Assassins

At its core, CRISPR-enhanced phage therapy marries two distinct biological marvels: bacteriophages and CRISPR-Cas systems. Bacteriophages, or phages, are nature's most abundant biological entities, viruses that specifically target and replicate within bacteria, ultimately lysing (bursting) them. They are highly specific, self-replicating at the site of infection, and can evolve alongside their bacterial hosts, offering a dynamic therapeutic advantage.

The challenge with native phages lies in their inherent limitations. A naturally occurring phage might be effective against one strain of Staphylococcus aureus but utterly useless against another. It might carry genes that confer resistance to other bacteria, or even genes that promote bacterial virulence. This variability and lack of precise control historically made broad clinical application difficult and regulatory approval a labyrinthine process.

Enter CRISPR-Cas, the precise gene-editing tool. Originally discovered as a bacterial immune system, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) allows for highly precise, programmable editing of DNA. When integrated into a phage genome, CRISPR-Cas transforms the phage into a sophisticated molecular engineer, capable of not just killing bacteria, but also altering their genetic makeup.

Imagine a phage engineered to carry a CRISPR-Cas system. When this 'CRISPR-phage' infects a target bacterium, it doesn't just replicate and destroy. It deploys its CRISPR payload to specifically target and disable bacterial resistance genes, or even virulence factors. This means the phage can not only kill the resistant bacterium but also disarm any surviving bacteria, making them susceptible to existing antibiotics. This dual action offers a path to re-sensitize pathogens once considered untreatable.

Furthermore, CRISPR can be used to engineer the phages themselves. Researchers can modify phage genomes to broaden their host range, enhance their lytic activity, prevent lysogeny (where the phage integrates into the bacterial genome rather than killing it), or even remove undesirable genes. This level of customization allows for the creation of 'designer phages' tailored to specific infections, reducing off-target effects and improving therapeutic efficacy. This is a level of control previously unattainable, moving beyond mere biological agents to sophisticated biological software.

Consider the implications for biofilm infections, notoriously difficult to treat due to their protective matrix and high resistance. CRISPR-phages could be engineered to degrade biofilm components, penetrate the matrix, and then precisely eliminate the embedded resistant bacteria. This multi-pronged attack addresses the fundamental challenges of chronic infections, offering hope where conventional treatments often fail.

Key Takeaway: CRISPR-Cas transforms phages from bacterial predators into highly programmable genetic surgeons. They are capable of not only eliminating resistant pathogens but also reversing antibiotic resistance, thereby unlocking unprecedented therapeutic control.

Market Implications: Rewriting the Antibiotic Rulebook

The market for infectious disease treatments, particularly those addressing antibiotic-resistant infections, is vast and underserved. The global market for antibiotics alone was valued at over $45 billion in 2023, with projections reaching $60 billion by 2030 [2]. Yet, this number only reflects the existing, increasingly ineffective arsenal. The true market potential for a truly effective solution against superbugs is significantly larger, as it would unlock treatments for conditions currently deemed untreatable or requiring extreme measures.

CRISPR-enhanced phage therapy stands to disrupt several established market segments. Firstly, it directly challenges the traditional antibiotic market by offering an alternative, and in many cases, superior, treatment for resistant infections. This isn't just about replacing existing drugs; it's about expanding the treatable population. Secondly, it creates an entirely new segment for personalized medicine in infectious diseases, where treatments can be rapidly designed and deployed against specific patient pathogens.

The economic burden of AMR is staggering, estimated to cost the U.S. healthcare system up to $55 billion annually [3]. Effective CRISPR-phage therapies could drastically reduce hospital stays, treatment failures, and the need for expensive, last-resort drugs. This translates into massive savings for healthcare providers and insurers, creating a powerful economic incentive for adoption once regulatory hurdles are cleared.

Furthermore, the technology's potential extends beyond human medicine. Agricultural applications, where antibiotic overuse contributed significantly to resistance, present another massive market. Imagine phages engineered to protect livestock or crops from bacterial pathogens, reducing the need for prophylactic antibiotics and enhancing food security. This dual-use potential significantly broadens the total addressable market (TAM) for companies developing these platforms.

However, the market's current valuation of companies in this sector often reflects a cautious, incremental view, rather than acknowledging the disruptive potential. Investors remain largely anchored to traditional drug development timelines and regulatory pathways, which may not fully capture the agility and adaptability inherent in a programmable biological system. This skepticism, while understandable given past biotech failures, overlooks the fundamental shift in capability CRISPR brings.

Consider the rapid development and deployment of mRNA vaccines during the pandemic. While not directly analogous, it demonstrated the potential for accelerated development and regulatory pathways for novel biological modalities when urgency and scientific breakthroughs align. The superbug crisis is arguably an even greater, albeit slower-burning, urgency.

---

The Architects: Cultivating the Microbe-Verse

The field of CRISPR-enhanced phage therapy is still nascent, but a handful of pioneering companies and academic institutions are laying the groundwork. These are the architects of the microbe-verse, building the tools and platforms that will define the next era of infectious disease treatment. The sector is characterized by a mix of specialized biotech startups and larger pharmaceutical players making strategic investments or acquisitions.

Here's a look at some key players, though the list is dynamic and constantly evolving:

Locus Biosciences is arguably one of the most advanced, having initiated a Phase 1b clinical trial for LBP-EC01. This CRISPR-Cas3-engineered bacteriophage product targets Escherichia coli in urinary tract infections (UTIs) [4]. Their approach focuses on delivering the CRISPR machinery via phage to specifically degrade bacterial DNA, offering a highly targeted and potent antimicrobial effect. This clinical progress positions them as a front-runner, demonstrating the feasibility of this complex technology in humans.

Adaptive Phage Therapeutics (APT) takes a slightly different, but equally compelling, approach with its PhageBank platform. Instead of engineering phages with CRISPR, APT focuses on rapidly identifying and deploying naturally occurring phages from its vast library that are effective against a patient's specific infection. While not strictly 'CRISPR-enhanced' in its primary offering, their rapid diagnostic and deployment capabilities could be augmented by CRISPR for further precision and resistance-reversal in the future. Their significant funding from the Department of Defense's DARPA program underscores the strategic importance of their work [5].

Companies like SNIPR Biome and Eligo Bioscience are exploring the broader implications of CRISPR-guided antimicrobials, particularly in the context of the microbiome. Their focus isn't just on killing pathogens but on precisely editing microbial communities, removing undesirable bacteria while preserving beneficial ones. This 'surgical' approach to microbiome modulation has profound implications for treating chronic diseases and maintaining health, moving beyond the blunt instrument of broad-spectrum antibiotics.

While CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) are primarily known for their work in genetic diseases, their foundational CRISPR platforms provide the intellectual property and expertise that could be leveraged for infectious disease applications. Any significant breakthrough in CRISPR-phage delivery or efficacy could see these larger players either entering the sector directly or acquiring promising startups to expand their therapeutic pipelines. The market often overlooks the modularity of these core technologies.

Key Takeaway: The current leaders are private biotechs making clinical headway. However, the underlying CRISPR platform companies hold significant long-term strategic value as the technology matures and applications broaden.

---

Investment Thesis: The Unseen Currents of Disruption

The prevailing market narrative suggests that antibiotic resistance is a slow-burn crisis, with incremental solutions. Our counter-narrative posits that CRISPR-enhanced phage therapy represents a fundamental, non-linear leap in infectious disease treatment. This makes it a compelling, albeit high-risk, investment opportunity. The market currently underprices the disruptive potential of programmable biological agents.

The Bull Case: The demand for effective superbug treatments is inelastic and growing. CRISPR-phage therapy offers unparalleled precision, the ability to reverse resistance, and a dynamic, evolving therapeutic platform. Companies that successfully navigate clinical trials and regulatory pathways will tap into a multi-billion-dollar market with significant unmet needs. Early movers with proprietary phage libraries, CRISPR delivery systems, and manufacturing capabilities will establish defensible moats. The potential for platform expansion into agriculture, veterinary medicine, and even industrial applications further amplifies the long-term value proposition. This isn't just a new drug; it's a new class of medicine.

The Bear Case: The regulatory path for living therapeutics, especially genetically modified ones, remains complex and uncertain. Manufacturing at scale, ensuring stability, and managing potential immunogenicity or off-target effects are significant technical hurdles. Public perception regarding genetically modified organisms (GMOs) could also present adoption challenges. Furthermore, the rapid evolution of bacteria means that even CRISPR-phages might face resistance over time, necessitating continuous development and adaptation. The capital requirements for clinical development are substantial, and many early-stage companies may fail to secure sufficient funding.

Conviction Level: High-Conviction, Long-Term Speculative. This is not for the faint of heart or those seeking immediate returns. This thesis requires a long-term horizon, an appetite for volatility, and a belief in the transformative power of biotechnology. We believe the fundamental scientific breakthroughs are too significant to be ignored, and the market's current skepticism creates an attractive entry point for those willing to embrace the future of medicine.

Specific investment opportunities lie in companies with robust intellectual property around CRISPR delivery via phages. These include those demonstrating early clinical efficacy, and those with scalable manufacturing solutions. Furthermore, companies developing advanced diagnostic tools that can rapidly identify bacterial strains and resistance profiles will be critical enablers of personalized phage therapy, representing an attractive adjacent investment.

Consider the potential for platform technology plays. Instead of betting on a single drug candidate, investing in companies that own the underlying CRISPR-phage engineering platforms allows for diversification across multiple potential therapeutic applications. This strategy mitigates some of the single-asset risk inherent in traditional biotech investing.

---

Challenges & Risks: Navigating the Microbe's Labyrinth

Investing in cutting-edge biotechnology is never without its perils, and CRISPR-enhanced phage therapy is no exception. The path from laboratory breakthrough to widespread clinical adoption is fraught with scientific, regulatory, and commercial challenges that demand a sober assessment.

Regulatory Labyrinth: Genetically modified living therapeutics represent a novel class of drugs, posing significant challenges for regulatory bodies like the FDA and EMA. Establishing clear guidelines for safety, efficacy, manufacturing, and long-term monitoring will be a protracted process. The modularity and potential for rapid modification of CRISPR-phages could complicate traditional approval pathways, which are designed for static chemical compounds. Each engineered phage might be considered a new drug, leading to prohibitive development costs and timelines.

Bacterial Counter-Evolution: Bacteria are masters of adaptation. While CRISPR-phages offer unprecedented precision, bacteria will inevitably evolve mechanisms to evade them. This could involve modifying the CRISPR target sequence, developing anti-CRISPR proteins, or altering surface receptors that phages use for entry. This necessitates a continuous 'arms race' of development, requiring companies to build platforms for rapid phage redesign and deployment, rather than relying on a static therapeutic.

Delivery and Immunogenicity: Ensuring the engineered phages reach the site of infection in sufficient concentrations and remain stable in vivo is crucial. Furthermore, the human immune system, while generally tolerant of phages, could mount a response against the viral vector or the CRISPR components, leading to reduced efficacy or adverse reactions. Careful engineering is required to minimize immunogenicity while maximizing therapeutic effect.

Manufacturing and Scalability: Producing highly specific, genetically engineered phages at pharmaceutical grade and scale is a significant undertaking. Quality control, batch-to-batch consistency, and cost-effective manufacturing processes are critical for commercial viability. The personalized nature of some phage therapies, where treatments are tailored to individual patients, presents unique logistical and manufacturing challenges that differ vastly from mass-produced small molecules.

Ethical and Public Perception: The use of genetically modified viruses, even for therapeutic purposes, could trigger public apprehension. Clear communication, transparent research, and robust safety data will be essential to build trust and acceptance. Ethical considerations around modifying the microbiome and the potential for unintended ecological consequences also need careful consideration and proactive management.

These are not insurmountable obstacles, but they are formidable. Companies that demonstrate a clear strategy for addressing these risks—through adaptive platform technologies, proactive regulatory engagement, and robust safety profiles—will be the ones that ultimately succeed. The market will reward those who can not only innovate but also translate that innovation into a reliable, scalable, and acceptable medical solution.

The Investment Angle: Cultivating a Microbe-Hunter Portfolio

For investors seeking exposure to this transformative field, a nuanced approach is essential. Direct investment in early-stage, private CRISPR-phage companies carries significant risk but also the potential for outsized returns. For broader market participation, a multi-pronged strategy focusing on platform technologies, enabling diagnostics, and potentially larger biotech players with relevant IP is advisable.

Platform Technology Pure-Plays: Look for companies that are developing the foundational tools for CRISPR-phage engineering, rather than just a single therapeutic candidate. These include firms with proprietary CRISPR-Cas variants optimized for bacterial editing, novel phage delivery systems, or advanced bioinformatics platforms for phage design. While many are currently private, monitoring their funding rounds and potential IPOs is key.

Enabling Technologies: The success of personalized phage therapy hinges on rapid and accurate diagnostics. Companies developing next-generation sequencing (NGS) platforms for bacterial identification, antimicrobial susceptibility testing (AST), and phage-matching algorithms are critical enablers. These firms provide the intelligence layer for precision medicine in infectious diseases.

Large Biotech/Pharma with CRISPR IP: While not direct phage therapy plays, major CRISPR developers like CRISPR Therapeutics (CRSP) and Intellia Therapeutics (NTLA) hold valuable intellectual property that could be applied or licensed for phage applications. They represent a more diversified, lower-risk entry point into the broader CRISPR ecosystem, with the potential for upside if they strategically enter the infectious disease sector.

Specialized ETFs (Future Consideration): As the field matures, expect specialized ETFs to emerge, offering diversified exposure to companies involved in phage therapy, CRISPR technologies, and infectious disease innovation. Currently, broader biotech ETFs (e.g., XBI, IBB) may offer indirect exposure, but without the targeted focus required for this specific thesis.

Geographic Focus: While much of the innovation is U.S.-centric, keep an eye on developments in Europe and Asia, particularly countries with a history of phage therapy research. Regulatory environments and funding landscapes can vary significantly, creating different opportunities and challenges.

This isn't a sector for passive investment. It demands continuous research, a deep understanding of the underlying science, and a keen eye for regulatory shifts. The true alpha will be generated by those who can identify the companies building the most robust, adaptable, and scalable platforms for programmable biological agents, rather than those simply chasing the next antibiotic.

Future Outlook: The Dawn of Programmable Pathogen Control

The future of infectious disease treatment, shaped by CRISPR-enhanced phage therapy, will look fundamentally different from today's. Within the next 2-5 years, we anticipate significant advancements on several fronts, moving from proof-of-concept to broader clinical validation and early commercialization.

Near-Term (2-3 Years): Expect to see more Phase 1/2 clinical trials initiated, demonstrating the safety and initial efficacy of CRISPR-phages for specific, highly resistant infections. These will particularly target those with limited treatment options (e.g., chronic UTIs, cystic fibrosis lung infections). Regulatory bodies will likely begin to establish clearer, albeit still evolving, frameworks for genetically engineered living therapeutics. Advances in rapid diagnostic platforms will also accelerate, becoming indispensable for personalized treatment selection.

Mid-Term (3-5 Years): We could see the first conditional or accelerated approvals for CRISPR-phage therapies targeting life-threatening, multi-drug resistant infections where no alternatives exist. This will be a pivotal moment, validating the technology and opening the floodgates for further investment and development. Manufacturing processes will become more streamlined, and the ability to rapidly design and produce 'phage cocktails' tailored to evolving resistance profiles will become a commercial reality. The application of CRISPR to modify phage host range and enhance lytic activity will become standard practice.

Long-Term (5+ Years): CRISPR-phage therapy could become a mainstream treatment option, potentially integrated into standard care protocols for a wide range of bacterial infections. The technology may evolve to include in situ gene editing of bacterial populations within the human microbiome, offering prophylactic solutions against recurrent infections or even targeted modulation for chronic conditions. The concept of 'programmable antibiotics' will be fully realized, allowing for dynamic, adaptive responses to emerging bacterial threats. This could fundamentally alter the trajectory of global public health, offering a sustainable solution to the antibiotic resistance crisis.

This isn't just about fighting superbugs; it's about establishing a new paradigm for interacting with the microbial world. We are on the cusp of an era where we can precisely control bacterial populations, not with chemical sledgehammers, but with molecular scalpels. The investment opportunity here is not merely in a new drug, but in a new operating system for biological control, a system that promises to redefine health and medicine for generations to come.

---

Conclusion: The Investment Playbook

Conclusion: The Phage-CRISPR Revolution – A Tale of Two Portfolios

Our deep dive into the burgeoning field of CRISPR-enhanced phage therapy reveals not just a scientific breakthrough, but a tectonic shift poised to redefine the battle against antimicrobial resistance. This isn't merely about new antibiotics; it's about a living, evolving weapon system, capable of real-time adaptation against bacterial foes. For investors, this presents a compelling dichotomy: companies poised to ride this wave to unprecedented heights, and those whose established paradigms are about to be thoroughly disrupted. The stakes are high, the science is cutting-edge, and the investment opportunities (and pitfalls) are equally sharp.

The Leader: Precision Strikes and Genomic Fortunes

When we talk about companies set to benefit from the CRISPR-enhanced phage therapy revolution, one name immediately springs to mind with the precision of a CRISPR-Cas9 complex itself: CRISPR Therapeutics (NASDAQ: CRSP). While not directly developing phage therapies, CRSP is a foundational intellectual property powerhouse in the CRISPR gene-editing space, holding critical patents and expertise that will be indispensable for the 'enhanced' part of this equation. Their competitive advantage stems from their robust patent portfolio surrounding the core CRISPR-Cas9 technology, their deep scientific bench in gene editing, and their proven ability to translate complex genomic science into clinical applications, as evidenced by their work in ex-vivo cell therapies. They are the picks and shovels provider for a gold rush that's just beginning.

Currently, CRSP boasts a market capitalization of approximately $5.5 billion, a figure that, while substantial, pales in comparison to the potential market size for a truly effective, adaptive solution to antibiotic resistance. Financially, they are well-capitalized, with over $1.7 billion in cash and equivalents as of their latest reports, providing a long runway for R&D and strategic partnerships. Their investment thesis is simple yet profound: as phage therapy evolves to incorporate real-time CRISPR-mediated resistance overcoming mechanisms, the demand for sophisticated, reliable, and legally sound CRISPR technology will skyrocket. CRSP is perfectly positioned to license its foundational IP, collaborate on novel delivery systems, or even acquire smaller phage therapy innovators, becoming the technological backbone of this new therapeutic modality. For an investor, CRSP offers exposure to the fundamental technology enabling the next generation of infectious disease treatment, rather than betting on a single phage cocktail. It's a bet on the platform, not just the product.

However, risks abound. CRSP's valuation is largely based on future potential, and any setbacks in broader gene editing clinical trials, intellectual property challenges, or the emergence of alternative gene-editing platforms could dampen enthusiasm. Furthermore, the regulatory pathway for living, adaptive therapies like CRISPR-enhanced phages is still nascent, posing potential hurdles. Nevertheless, their strategic position as a core technology provider makes them a compelling long-term play in this evolving landscape.

The Lagger: The Antibiotic Empire's Cracks

On the flip side, the very companies that have historically dominated the infectious disease market with broad-spectrum antibiotics are staring down an existential threat. Our prime candidate for

---

Parting Thoughts

As always, the future belongs to those who prepare for it today. Stay curious, stay invested, and stay tuned.

— The Vetta Research Team

---

1. World Health Organization, "Antimicrobial resistance," WHO, 2023, https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
2. Grand View Research, "Antibiotics Market Size, Share & Trends Analysis Report," Grand View Research, 2023, https://www.grandviewresearch.com/industry-analysis/antibiotics-market
3. Centers for Disease Control and Prevention, "Antibiotic Resistance Threats in the United States, 2019," CDC, 2019, https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
4. Locus Biosciences, "Locus Biosciences Announces Initiation of Phase 1b Clinical Trial for LBP-EC01," Locus Biosciences, 2020, https://www.locusbio.com/news/locus-biosciences-announces-initiation-of-phase-1b-clinical-trial-for-lbp-ec01/
5. Adaptive Phage Therapeutics, "Adaptive Phage Therapeutics Awarded Up To $25 Million from DoD's DARPA for PhageBank Development," Adaptive Phage Therapeutics, 2020, https://www.aphage.com/news/adaptive-phage-therapeutics-awarded-up-to-25-million-from-dods-darpa-for-phagebank-development/
6. CRISPR Therapeutics, "Pipeline," CRISPR Therapeutics, 2024, https://crisprtx.com/our-pipeline
7. Intellia Therapeutics, "Our Pipeline," Intellia Therapeutics, 2024, https://www.intelliatx.com/our-pipeline/
8. SNIPR Biome, "Technology," SNIPR Biome, 2024, https://www.sniprbiome.com/technology/

---

Sources & References

1. Vetta Research, "Sector Company Filings & Investor Relations Disclosures," Primary Research, 2026
2. Industry Research Providers, "Sector Market Data & Analysis," Industry Analysis, 2026
3. SEC EDGAR, "Company Financial Filings," U.S. Securities and Exchange Commission, 2026, https://www.sec.gov/cgi-bin/browse-edgar
4. Government & Academic Sources, "Peer-Reviewed Publications & Agency Reports," Various, 2026
5. Reuters / Financial Times / Wall Street Journal, "Financial News Reporting," Major Press, 2026

All sources were verified at the time of publication. For specific citations, contact [email protected].

---

Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. Vetta Investments does not guarantee the accuracy, completeness, or timeliness of any information presented. Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Readers should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. Vetta Investments may hold positions in securities mentioned in this article.